225 related articles for article (PubMed ID: 34655242)
21. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
22. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution.
Chatzispyrou IA; Guerrero-Castillo S; Held NM; Ruiter JPN; Denis SW; IJlst L; Wanders RJ; van Weeghel M; Ferdinandusse S; Vaz FM; Brandt U; Houtkooper RH
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3650-3658. PubMed ID: 30251684
[TBL] [Abstract][Full Text] [Related]
23. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S
Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945
[TBL] [Abstract][Full Text] [Related]
25. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome.
Dudek J; Cheng IF; Balleininger M; Vaz FM; Streckfuss-Bömeke K; Hübscher D; Vukotic M; Wanders RJ; Rehling P; Guan K
Stem Cell Res; 2013 Sep; 11(2):806-19. PubMed ID: 23792436
[TBL] [Abstract][Full Text] [Related]
26. Blocking phosphatidylglycerol degradation in yeast defective in cardiolipin remodeling results in a new model of the Barth syndrome cellular phenotype.
Káňovičová P; Čermáková P; Kubalová D; Bábelová L; Veselá P; Valachovič M; Zahumenský J; Horváth A; Malínský J; Balážová M
J Biol Chem; 2022 Jan; 298(1):101462. PubMed ID: 34864056
[TBL] [Abstract][Full Text] [Related]
27. Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice.
Cole LK; Kim JH; Amoscato AA; Tyurina YY; Bay R H; Karimi B; Siddiqui TJ; Kagan VE; Hatch GM; Kauppinen TM
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3353-3367. PubMed ID: 30055293
[TBL] [Abstract][Full Text] [Related]
28. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
[TBL] [Abstract][Full Text] [Related]
29. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
30. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
31. Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.
Petit PX; Ardilla-Osorio H; Penalvia L; Rainey NE
Cells; 2020 Oct; 9(10):. PubMed ID: 33096711
[TBL] [Abstract][Full Text] [Related]
32. Barth syndrome mutations that cause tafazzin complex lability.
Claypool SM; Whited K; Srijumnong S; Han X; Koehler CM
J Cell Biol; 2011 Feb; 192(3):447-62. PubMed ID: 21300850
[TBL] [Abstract][Full Text] [Related]
33. Cardiac metabolic pathways affected in the mouse model of barth syndrome.
Huang Y; Powers C; Madala SK; Greis KD; Haffey WD; Towbin JA; Purevjav E; Javadov S; Strauss AW; Khuchua Z
PLoS One; 2015; 10(6):e0128561. PubMed ID: 26030409
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial dysfunctions in barth syndrome.
Ghosh S; Iadarola DM; Ball WB; Gohil VM
IUBMB Life; 2019 Jul; 71(7):791-801. PubMed ID: 30746873
[TBL] [Abstract][Full Text] [Related]
35. Tafazzin deficiency attenuates anti-cluster of differentiation 40 and interleukin-4 activation of mouse B lymphocytes.
Zegallai HM; Abu-El-Rub E; Mejia EM; Sparagna GC; Cole LK; Marshall AJ; Hatch GM
Cell Tissue Res; 2022 Dec; 390(3):429-439. PubMed ID: 36129532
[TBL] [Abstract][Full Text] [Related]
36. Seven functional classes of Barth syndrome mutation.
Whited K; Baile MG; Currier P; Claypool SM
Hum Mol Genet; 2013 Feb; 22(3):483-92. PubMed ID: 23100323
[TBL] [Abstract][Full Text] [Related]
37. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai HM; Hatch GM
Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
[TBL] [Abstract][Full Text] [Related]
38. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
[TBL] [Abstract][Full Text] [Related]
39. NAD supplementation improves mitochondrial performance of cardiolipin mutants.
Ji J; Damschroder D; Bessert D; Lazcano P; Wessells R; Reynolds CA; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Apr; 1867(4):159094. PubMed ID: 35051613
[TBL] [Abstract][Full Text] [Related]
40. Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-
Suzuki-Hatano S; Sriramvenugopal M; Ramanathan M; Soustek M; Byrne BJ; Cade WT; Kang PB; Pacak CA
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
